(a) Clotrimazole 500 mg vaginal ovules perimenstrually (once a month prophylactically), plus for symptomatic episodes in between. Patients with a history of recurrent symptoms before the menses were advised to insert the ovule 5-7 days before the expected menses. For patients with symptoms usually occurring after the menses, the ovule was inserted the last day of the period.
(b) Empiric self-treatnent with single doses of clotrimazole 500 mg ovules at onset 
Discussion
There is no known permanent cure for recurrent vulvovaginal candidiasis, and a variety of therapeutic modalities have been tried without success.' Chronic suppressive (or prophylactic) therapy intermittently or continuously for several months has been used with success to control the patients' symptoms. However, after discontinuation of the prophylactic or suppressive therapy most patient will continue to have recurrences.3-5 Davidson and Mould3 first showed that intermittent suppressive therapy with clotrimazole (cream and pessaries) on the 5th to 11th day of the menstrual cycle was effective in reducing symptomatic disease. In this study, only a single clotrimazole (500 mg) pessary was used, as this has been shown to be effective as a single dose therapy for acute Candida vaginitis. The timing of the prophylactic doses in this study depended on the pattern of recurrences of the previous vaginitis episodes and was, thus, individualised to the patient's needs.
In this study, patients with chronic recurrent vaginal candidiasis were used as their own controls, thus decreasing the interpatient variability. During 6 months of prophylactic therapy (138 patients months), there was a 30% reduction of symptomatic vaginitis episodes, and 42% of the symptoms during this period occurred at the time prophylaxis was being instituted (Gust before or after the menses) and did not require extra treatment. However, there was significantly less amount of clotrimazole ovules used during the empiric self-treatment period, compared with the prophylactic period, resulting in a 50% cost saving for the medication alone.
On assessing the patients' personal preference to the regimens used, the vast majority (74%) preferred the empiric self-treatment strategy over the cyclical prophylactic method.
One of the limitations of this study is the small sample size (and some may argue, the cross-over design). However, the variability of data obtained with this design is less than that associated with the parallel design. Withinpatient differences are used to assess treatment differences in a cross-over trial. Because of its increased sensitivity and small variability, the cross over design requires fewer patients than does the parallel design to detect the same effect.6 The patients in this study had a chronic stable condition, and similar baseline condition was present at the start of two treatment periods. Moreover, neither form of treatment strategy was likely to have any residual or carryover effect. Also randomisation of the type of treatment period initiated should obviate any selection bias.
In summary, although perimenstrual clotrimazole prophylactically may decrease the number of symptomatic vaginitis episodes, empiric self-treatment was more cost effective and the preferred strategy by the majority of patients with chronic recurrent vaginal candidiasis. For patients with at least twelve episodes per year, the prophylactic strategy may be more beneficial.
